Novartis AG (NOVN.SW)

89,50 -0,50 (-0,56%) Al cierre: 05:31PM CEST

Novartis AG

Lichtstrasse 35
Basel 4056
Switzerland
41 61 324 1111
https://www.novartis.com

Sector(es): Healthcare
Sector: Drug Manufacturers - General
Empleados a tiempo completo: 76.057

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Vasant Narasimhan M.D.	Chief Executive Officer	7,33M	N/A	1976
Mr. Harry Kirsch	Chief Financial Officer	3,65M	N/A	1965
Mr. Victor Bulto	President of US	3M	N/A	1978
Dr. Patrick Horber M.D.	President of International	6,68M	N/A	1970
Dr. Steffen Lang Ph.D.	President of Operations	2,14M	N/A	1967
Paul Penepent	Head of Group Financial Reporting and Accounting	N/A	N/A	N/A
Dr. Samir Shah M.D.	Global Head of Investor Relations	N/A	N/A	1962
Dr. Klaus Moosmayer Ph.D.	Chief Ethics, Risk & Compliance Officer	1,42M	N/A	1968
Ms. Karen L. Hale	Chief Legal Officer	2,14M	N/A	1968
Dr. Robert Kowalski Pharm.D.	Chief People & Organization Officer	1,92M	N/A	1968

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en CHF.

Descripción

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Gobierno corporativo

El ISS Governance QualityScore de Novartis AG, a día 1 de abril de 2024, es 1. Las puntuaciones base son Auditoría: 1; Tablero: 2; Derechos de los accionistas: 1; Compensación: 3.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.